Revolution Medicines, Inc.

For the period ended Mar 31, 2026. Filed May 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 6, 2026

RVMD$200.15+4.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

	March 31,	December 31,
	2026	2025
Assets
Current assets:
Cash and cash equivalents	$440,939	$383,745
Marketable securities	1,467,145	1,641,934
Prepaid expenses and other current assets	59,829	49,358
Total current assets	1,967,913	2,075,037
Property and equipment, net	31,475	33,194
Operating lease right-of-use asset	129,895	132,084
Intangible assets, net	55,800	55,800
Goodwill	14,608	14,608
Restricted cash	4,858	4,858
Long-term deposits	34,709	24,148
Other noncurrent assets	14,479	14,779
Total assets	$2,253,737	$2,354,508
Liabilities and stockholdersʼ equity
Current liabilities:
Accounts payable	$80,538	$64,616
Accrued expenses and other current liabilities	192,451	209,340
Operating lease liability, current	16,610	16,468
Total current liabilities	289,599	290,424
Deferred tax liability	2,353	2,353
Operating lease liability, noncurrent	140,019	142,234
Liability related to the sale of future royalties	280,643	268,446
Warrant liability	34,327	18,546
Other noncurrent liabilities	6,879	1,208
Total liabilities	753,820	723,211
Commitments and contingencies (Note 7)
Stockholdersʼ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; none issued and outstanding at March 31, 2026 and December 31, 2025, respectively	—	—
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 200,178,626 and 197,001,401 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	19	19
Additional paid-in capital	4,823,438	4,497,143
Accumulated other comprehensive income (loss)	(622)	3,237
Accumulated deficit	(3,322,918)	(2,869,102)
Total stockholdersʼ equity	1,499,917	1,631,297
Total liabilities and stockholdersʼ equity	$2,253,737	$2,354,508

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.